PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates
to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh
Inc. nor any other party involved in the preparation of this program shall be
liable for any special, consequential, or exemplary damages resulting in whole
or part from any user's use of or reliance upon this material. Please read the
disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING
THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE
Initial U.S. Approval: 2010 DESCRIPTION
LASTACAFT® is a sterile, topically administered H1 receptor antagonist
containing alcaftadine for ophthalmic use.
Contains: Active: alcaftadine 0.25% (2.5 mg/mL). Preservative:
benzalkonium chloride 0.005%. Inactives: edetate disodium; sodium
phosphate, monobasic; purified water; sodium chloride; sodium hydroxide
and/or hydrochloric acid to adjust pH.
The drug product has a pH of approximately 7 and an osmolality of
approximately 290 mOsm/kg.
CLINICAL PHARMACOLOGY Mechanism of Action
Alcaftadine is an H1 histamine receptor antagonist and inhibitor of the
release of histamine from mast cells. Decreased chemotaxis and
inhibition of eosinophil activation has also been demonstrated.
INDICATIONS AND USAGE
LASTACAFT® is an H1 histamine receptor antagonist indicated for
the prevention of itching associated with allergic
------------------------------------ Contamination of Tip and Solution
To minimize contaminating the dropper tip and solution, care
should be taken not to touch the eyelids or surrounding areas
with the dropper tip of the bottle. Keep bottle tightly closed
when not in use.
Contact Lens Use
Patients should be advised not to wear a contact lens if their
eye is red. LASTACAFT® should not be used to treat contact
LASTACAFT® should not be instilled while wearing contact lenses.
Remove contact lenses prior to instillation of LASTACAFT®. The
preservative in LASTACAFT®, benzalkonium chloride, may be
absorbed by soft contact lenses. Lenses may be reinserted after
10 minutes following administration of LASTACAFT®.
Topical Ophthalmic Use Only
LASTACAFT® is for topical ophthalmic use only.
WARNINGS AND PRECAUTIONS
To minimize the risk of contamination, do not touch dropper tip
to any surface. Keep bottle tightly closed when not in use.
LASTACAFT® should not be used to treat contact lens-related
Remove contact lenses prior to instillation of LASTACAFT®.